About Seres Therapeutics, Inc. - Common Stock (MCRB)
Seres Therapeutics is a biotechnology company focused on developing innovative therapeutics that harness the power of the microbiome to treat various diseases, particularly gastrointestinal disorders. The company leverages its proprietary platform to identify and develop next-generation microbiome-based treatments, aiming to restore microbial balance in the human body and improve patient outcomes. Through its research and clinical programs, Seres strives to address unmet medical needs with transformative therapies that have the potential to change the standard of care in multiple therapeutic areas. Read More
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Halper Sadeh LLC, an investor rights law firm, is investigating whether Seres Therapeutics, Inc.’s (NASDAQ: MCRB) sale of its VOWST microbiome therapeutic business to Société des Produits Nestlé S.A is fair to Seres shareholders.
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2024 financial results and provided business updates.
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on May 1, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 9,367 shares of its common stock to two new employees, consisting of stock options to purchase 6,244 shares of common stock and restricted stock units (“RSUs”) covering 3,123 shares of its common stock.
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m. ET to discuss first quarter 2024 financial results and provide business updates.
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT). SER-155 is an orally administered, consortium of bacteria, cultivated from cell banks and designed to reduce the incidence and severity of enteric-derived infections and resulting bloodstream infections, including those that may harbor antibiotic resistance. Infections are a leading cause of mortality and morbidity in this immunocompromised patient population. SER-155 is also designed to induce immune tolerance responses to reduce the incidence of GvHD.
